Allosteric Modulators Market Global Report 2026

The allosteric modulators market size has grown rapidly in recent years. It will grow from $1.82 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to growing demand for safer alternative mechanisms in drug development, early-stage research in receptor binding modulation, increasing focus on neurological disorder treatment innovation, advancements in G-protein coupled receptor studies, and expansion of small molecule drug discovery programs.

The allosteric modulators market size is expected to see rapid growth in the next few years. It will grow to $3.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to the expansion of AI-enabled drug discovery platforms, increasing investments in precision medicine and targeted therapeutic development, rising number of clinical trials focused on allosteric modulators, growth in computational biology and structural pharmacology capabilities, and increasing demand for highly selective drugs with reduced side effects. Major trends in the forecast period include wider adoption of structure-based drug design for identifying allosteric modulators, growing utilization of computational chemistry and AI-based molecular screening for receptor targeting, expansion of allosteric modulator research in neurological disorder treatments, rising development of highly selective receptor subtype-specific modulators, and increasing pharmaceutical focus on next-generation safer non-orthosteric drug mechanisms.

The increasing burden of neurological disorders and disability is expected to propel the growth of the allosteric modulators market going forward. Neurological disorders and disability refer to medical conditions affecting the brain, spinal cord, and nervous system that result in cognitive, sensory, or physical impairments. The burden of neurological disorders and disability is increasing due to rising chronic disease prevalence and growing lifestyle related health risks. Allosteric modulators are used in neurological disorders to regulate receptor activity and improve neurotransmission, helping manage conditions such as epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders. For instance, in March 2024, according to the Alzheimer’s Association, a US-based nonprofit health organization, an estimated 6.9 million Americans aged 65 years and older were living with Alzheimer’s disease in 2024, compared to 6.7 million in 2023, reflecting a notable year-on-year increase in disease prevalence. Therefore, the increasing burden of neurological disorders and disability is driving the growth of the allosteric modulators market.

The increasing healthcare spending is expected to propel the growth of the allosteric modulators market going forward. Healthcare spending refers to the total expenditure on medical services, treatments, healthcare infrastructure, pharmaceuticals, and related activities aimed at maintaining or improving health. Healthcare spending is rising due to the increasing prevalence of chronic diseases, as long-term conditions such as diabetes, cardiovascular disorders, and cancer require continuous medical care, advanced treatments, and prolonged hospitalization. Higher healthcare spending supports allosteric modulators by expanding funding and reimbursement capacity for advanced precision therapies, enabling greater investment in research, clinical trials, and adoption of novel mechanism-based drugs that target diseases with improved specificity and fewer side effects. For instance, in April 2026, according to the Office for National Statistics, a UK-based government agency, healthcare spending accounted for 11.4% of GDP in 2025, up from 11.1% in 2024. Therefore, the increasing healthcare spending is driving the growth of the allosteric modulators market.

Leading companies operating in the allosteric modulators market are focusing on developing innovative solutions, such as selective allosteric modulator therapeutics to meet the rising demand for safer and more targeted neurological disorder treatments. Selective allosteric modulators bind to receptor sites different from traditional active binding sites enabling improved precision enhanced efficacy and reduced side effects compared to conventional drugs. For example, in April 2024, Neurosterix, a US-based biopharmaceutical company, launched an advanced allosteric modulator drug discovery platform supported by 63 million dollars in Series A financing. The platform focuses on developing highly selective brain-penetrant small molecule therapies including M4 positive allosteric modulators for schizophrenia and other neurological disorders. The technology utilizes high-throughput discovery tools to accelerate the development of next-generation neurological therapeutics with improved tolerability and therapeutic precision.

Major companies operating in the allosteric modulators market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Neurocrine Biosciences Inc., Intra-Cellular Therapies, Biohaven Ltd., Nxera Pharma, Kainova Therapeutics, Saniona AB, Addex Therapeutics Ltd., Confo Therapeutics NV.

Asia-Pacific was the dominant region in the allosteric modulators market in 2025 and is expected to be the rapidly expanding region in the forecast period. The regions covered in allosteric modulators report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allosteric modulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allosteric modulators market consists of sales of G protein-coupled receptor (GPCR) modulators, ion channel modulators, enzyme modulators, receptor-targeted therapeutics, and small molecule allosteric drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The allosteric modulators market research report is one of a series of new reports that provides allosteric modulators market statistics, including allosteric modulators industry global market size, regional shares, competitors with a allosteric modulators market share, detailed allosteric modulators market segments, market trends and opportunities, and any further data you may need to thrive in the allosteric modulators industry. This allosteric modulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.